Literature DB >> 16287141

Younger birth cohort correlates with higher breast and ovarian cancer risk in European BRCA1 mutation carriers.

Regina Kroiss1, Verena Winkler, Diana Bikas, Elisabeth Fleischmann, Claudia Mainau, Florian Frommlet, Daniela Muhr, Christine Fuerhauser, Maria Tea, Barbara Bittner, Ernst Kubista, Peter J Oefner, Peter Bauer, Teresa M U Wagner.   

Abstract

Mutations in the BRCA1 gene result in an elevated risk of breast cancer (BC) and ovarian cancer (OC). However, risk estimates vary depending on the study population and statistical methodology used, and there are indications that the birth cohort and location of the mutation influence cancer risk. We investigated the risks for BC and OC associated with BRCA1 mutations in a young cohort of female mutation carriers who were identified by molecular genetic testing and belonged to a genetically heterogeneous Central European population. The study included 106 healthy and 158 affected carriers identified at an Austrian risk evaluation center. Risk estimation employed the product limit method. The log rank test was used to compare different strata. The risk of developing cancer to age 70 was found to be 85% for BC (95% CI 75-97%) and 53% for OC (95% CI 37-68%). Female mutation carriers born in 1958 or later were subject to a significantly higher risk of BC (P=0.005; 27% vs. 46% to age 40) and OC (P=0.006; 2% vs. 8% to age 40) than those born earlier. Mutations in exon 11 were associated with lower BC risk than mutations in exons 1-10 (P=0.008) and exons 12-24 (P=0.0006). OC risk was not influenced by mutation location (P=0.86). We conclude that female BRCA1 mutation carriers should be counseled about their cohort-dependent cancer risk. Further research into variables that affect cancer risk and are amenable to modification (e.g., lifestyle-related factors) should be considered a priority. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 16287141     DOI: 10.1002/humu.20261

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  9 in total

Review 1.  Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers.

Authors:  Janet R Vos; Li Hsu; Richard M Brohet; Marian J E Mourits; Jakob de Vries; Kathleen E Malone; Jan C Oosterwijk; Geertruida H de Bock
Journal:  J Clin Oncol       Date:  2015-07-06       Impact factor: 44.544

2.  Prevalence of pre-malignant and malignant lesions in prophylactic mastectomy specimens of BRCA1 mutation carriers: comparison with a control group.

Authors:  Regina Kroiss; V Winkler; K Kalteis; D Bikas; M Rudas; M Tea; C Fuerhauser; D Muhr; H Cerny; S Glueck; E Petru; H Concin; E Kubista; P Oefner; T Wagner
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-08       Impact factor: 4.553

3.  Profiling of Cross-Functional Peptidases Regulated Circulating Peptides in BRCA1 Mutant Breast Cancer.

Authors:  Jia Fan; Muy-Kheng M Tea; Chuan Yang; Li Ma; Qing H Meng; Tony Y Hu; Christian F Singer; Mauro Ferrari
Journal:  J Proteome Res       Date:  2016-04-26       Impact factor: 4.466

4.  BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients.

Authors:  Fatemeh Keshavarzi; Gholam Reza Javadi; Sirous Zeinali
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

5.  Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.

Authors:  Sharon Simchoni; Eitan Friedman; Bella Kaufman; Ruth Gershoni-Baruch; Avi Orr-Urtreger; Inbal Kedar-Barnes; Ronit Shiri-Sverdlov; Efrat Dagan; Sigal Tsabari; Mordechai Shohat; Raphael Catane; Mary-Claire King; Amnon Lahad; Ephrat Levy-Lahad
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-28       Impact factor: 11.205

6.  A comprehensive reference for BRCA1/2 genes pathogenic variants in Iran: published, unpublished and novel.

Authors:  Keivan Majidzadeh-A; Shiva Zarinfam; Nasrin Abdoli; Fatemeh Yadegari; Rezvan Esmaeili; Leila Farahmand; Azin Teimourzadeh; Mahdieh Taghizadeh; Mansoor Salehi; Mohamad Zamani
Journal:  Fam Cancer       Date:  2021-03-23       Impact factor: 2.375

7.  Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction.

Authors:  Barbara Wappenschmidt; Alexandra A Becker; Jan Hauke; Ute Weber; Stefanie Engert; Juliane Köhler; Karin Kast; Norbert Arnold; Kerstin Rhiem; Eric Hahnen; Alfons Meindl; Rita K Schmutzler
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

8.  Prevalence of the most frequent BRCA1 mutations in Polish population.

Authors:  Izabela Brozek; Celina Cybulska; Magdalena Ratajska; Magdalena Piatkowska; Anna Kluska; Aneta Balabas; Michalina Dabrowska; Dorota Nowakowska; Anna Niwinska; Jolanta Pamula-Pilat; Karolina Tecza; Wioletta Pekala; Jolanta Rembowska; Karina Nowicka; Maria Mosor; Danuta Januszkiewicz-Lewandowska; Jadwiga Rachtan; Ewa Grzybowska; Jerzy Nowak; Jan Steffen; Janusz Limon
Journal:  J Appl Genet       Date:  2011-04-19       Impact factor: 3.240

9.  Effect of lifestyle and reproductive factors on the onset of breast cancer in female BRCA 1 and 2 mutation carriers.

Authors:  Viktoria Rieder; Mohamed Salama; Lena Glöckner; Daniela Muhr; Andreas Berger; Muy-Kheng Tea; Georg Pfeiler; Christine Rappaport-Fuerhauser; Daphne Gschwantler-Kaulich; Sigrid Weingartshofer; Christian F Singer
Journal:  Mol Genet Genomic Med       Date:  2015-12-10       Impact factor: 2.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.